New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer

MeSH terms

• Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
• Antineoplastic Combined Chemotherapy Protocols / adverse effects*
• Capecitabine
• Clinical Trials, Phase II as Topic*
• Denmark
• Deoxycytidine / administration & dosage
• Deoxycytidine / adverse effects
• Deoxycytidine / analogs & derivatives
• Diarrhea / chemically induced
• Diarrhea / prevention & control
• Docetaxel
• Drug Administration Schedule
• Esophageal Neoplasms / drug therapy*
• Esophageal Neoplasms / pathology
• Fever / etiology
• Fluorouracil / administration & dosage
• Fluorouracil / adverse effects
• Fluorouracil / analogs & derivatives
• Humans
• Neutropenia / chemically induced
• Neutropenia / complications
• Neutropenia / prevention & control*
• Organoplatinum Compounds / administration & dosage
• Organoplatinum Compounds / adverse effects
• Oxaliplatin
• Peripheral Nervous System Diseases / chemically induced
• Peripheral Nervous System Diseases / prevention & control
• Practice Guidelines as Topic / standards*
• Stomach Neoplasms / drug therapy*
• Stomach Neoplasms / pathology
• Survival Analysis
• Taxoids / administration & dosage
• Taxoids / adverse effects
• Treatment Outcome